In recent years, non-IgG antibodies exhibit certain therapeutic advantages over widely applied IgG monoclonal antibodies in tumors, infections, and inflammation. To further investigate and offer better services for non-IgG antibodies, Creative Biolabs has specially constructed a professional platform to provide non-IgG antibody production and purification services for customers in need.
IgM Production
Creative Biolabs utilizes both recombinant and hybridoma-based platforms for versatile IgM antibody production, accommodating diverse research needs across multiple species. Our advanced expression system platform is based on several high-performance cell lines:
The process includes gene synthesis, vector construction, plasmid preparation, and transient transfection or stable cell line development. This workflow produces IgM in pentameric or hexameric forms with appropriate disulfide bonding and J-chain formation, ensuring structural integrity and functional efficacy. We also provide traditional hybridoma technology options, including human-human and hetero-hybridomas, for reliable IgM production.
IgM Purification
Purification of IgM presents unique challenges due to its structural complexity and large molecular size, which renders typical protein A/G affinity chromatography ineffective. To address this, Creative Biolabs offers advanced purification strategies tailored for IgM:
Fig.1 A process of our
IgM production and purification.
IgM is the earliest antibody class expressed in the human fetus, and it is also the major isotype produced at the early stage in the primary response to antigens. In general, IgMs are produced by the immune system and play an important role in both innate and adaptive humoral immune responses. Just similar to other types of antibody molecules, IgM monomeric molecular consists of two identical heavy chains (μ) and two light chains (κ or λ). The predominant form of IgM in human serum is pentamer (~950 kDa) which is composed of five monomers connected with the joining-(J) chain. The other forms, such as hexamers (~1100kDa) and monomers (~170kDa), can also be found at rather a low abundance in vivo.
As an alternative therapeutic agent for IgG, IgM therapy benefits from the superior mobilization of effector functions. It has been found that IgM in pentameric form is the most efficient in the classical pathway of complement system activation. What's more, mucosal immunity can be attained by the transfer of IgM through the epithelial barrier. Besides the immune protective effect, IgM antibody exhibits great therapeutic potential in the treatment of various tumors both in laboratory and clinical research. Therefore, a large amount of high-quality IgM is necessary for pre-clinical and clinical testing.
Fig.1 Structure of IgG; pentameric IgM; and hexameric IgM.1
A: Creative Biolabs offers both recombinant and hybridoma-based IgM production systems. Recombinant production utilizes cell lines such as CHO, HEK293, and PER.C6, enabling high-yield, species-specific IgM production. Hybridoma-based systems include traditional and human-human hybridomas, allowing for diverse options tailored to research needs.
A: Creative Biolabs provides several advanced IgM purification methods, including a three-step ion exchange strategy, a two-step PEG-based approach, size exclusion chromatography (SXC), and the Capture Select method. Each method is optimized for high purity and recovery rates suited for different applications, including clinical-grade IgM.
A: IgM purification is complex due to its large molecular size and structure, making conventional protein A/G affinity chromatography ineffective. Creative Biolabs uses specialized methods such as ceramic hydroxyapatite enrichment, PEG precipitation, and Capture Select to achieve high purity and recovery, ensuring the IgM retains its functional integrity.
A: Creative Biolabs ensures structural integrity in IgM antibodies by incorporating disulfide bonding and J-chain formation during production. This approach yields pentameric or hexameric forms with complete structural and functional efficacy, which is essential for therapeutic and research applications.
A: IgM demonstrates superior mobilization of effector functions, particularly in classical complement pathway activation, and can achieve mucosal immunity through epithelial barrier transfer.
Based on our comprehensive antibody platforms and professional experts, Creative Biolabs has absolute advantages in providing non-IgG antibody production and purification services. Additionally, our ready-made/custom non-IgG antibody products and related services will help you achieve milestone development. Just directly contact us if you are interested, and our scientist will customize the most suitable solutions for your programs.
Our customer service representatives are available 24/7/365. You may contact us anytime for assistance. Orders can be placed online, over the phone, by email, or by fax.
Reference
For Research Use Only. Our products and services are NOT intended for diagnostic or therapeutic applications.